Asembia’s Specialty Pharmacy Summit remains the undisputed champion for conducting business in the specialty marketplace. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc.. or the author on the investment prospects of specific companies. New treatments aimed at rare diseases (also known as ‘orphan drugs’) are also emerging at a pace much faster than most other drugs. Die Erhebung wird in der Kategorie Rx seit dem Jahr 2000 in Deutschland jährlich bei niedergelassenen Ärzten und seit 2018 in den Kategorien OTC (Apotheker und Patienten), Orphan Drugs (Klinikärzte) und Startups sowie seit 2019 in der Kategorie Specialty Care (Klinikärzte) zusätzlich durchgeführt. So far, only 16 biosimilars have received FDA approval, of those, only six have reached the … In general, drugs covered under the pharmacy benefit are self-administered; that is, the patient takes them on their own. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. There was a 60.4% increase in utilization, a 37.4% increase in costs and a 4.9% increase in new medications. Moreover, fast-track development of new pharmaceutical industries, major merges and acquisitions among pharmacies, and improvement in pharmacy benefit management (PBM) and healthcare plans, are anticipated to bring about consolidation in the specialty pharmaceuticals market. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. The healthcare system is shifting in its pharmaceutical delivery model, with more targeted, high dollar therapies procured through specialty pharmacy. It is not intended to promote the use of any drug mentioned in the article and neither the author nor OptumRx has accepted any form of compensation for the preparation or distribution of this article. Emerging oncology treatments, particularly immunotherapy, are a major medical pharmacy trend driver. According to Express Scripts 2007 Drug Trend Report in 2007 there was a 14% increase in specialty drugs. 6. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. In 2018, two new drugs were approved to treat polyneuropathy due to Hereditary ATTR (hATTR) amyloidosis, a rare disease estimated to impact 10,000 people worldwide.6, The drugs, Onpattro® and Tegsedi™, employ variants of RNA therapy to transfer bits of genetic code to prevent production of the mutated TTR protein, which halts the disease. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. The global trends of open innovation, fast growing emerging markets, and patent cliff threat provides ample opportunity for smaller specialty pharma companies to gain the upper hand provided that the technology platforms or specialty medicinal products is what the big pharma wants. Specialty Pharmacy; Roadblocks and Remedies: Succeeding in Health System Special... Over the past decade, health systems have invested in specialty pharmacies at a growing rate. For example, Optum Specialty Pharmacy's hemophilia and bleeding disorders-specific program provides new hemophilia patients with a dedicated nurse navigator and concierge teams in order to deliver a world-class member experience. 8. The specialty pharmacy world is placing a greater focus on the needs of individual patients. The first approved DNA-altering gene therapy, Luxturna™, treats an inherited form of vision loss known as retinal dystrophy. 2020. Specialty Pharmacy Providers: Manufacturer Engagement and Contracting Trends June 2020. Key examples include two biosimilars recently launched for the popular cancer drugs, Avastin® and Herceptin®.4. For example, the makers of Humira® used legal settlements to delay the introduction of biosimilars until 2023.3. Specialty pharmacy, By 2008 there were more than 200 specialty pharmaceuticals on the market. While they are relatively recent, some have been on the market long enough to have outlived the usual period of market exclusivity. Click here if you can’t see the video below. 10,11 However, when there is only a single biosimilar competing against a branded biologic the price savings currently hovers around just 15%.2, “Everybody expects a generic to be at a lower cost —a significantly lower cost— than what the branded drug is,” says OptumRx senior vice president of specialty pharmacy, Michael Zeglinski. Your system will expect you to procure them and have health plans reimburse you for them. An overview of the drivers of change in specialty pharmacy. “With biosimilars, we are not seeing that.”, The lack of biosimilars is linked to these price discrepancies by a thicket of legal challenges and patents that biosimilar makers face. We have created a suite of therapy-specific programs designed to offer specialty patients dedicated support for specific disease states. Both therapies cost several hundred thousand dollars per patient per year and must be administered for life. do not make investment recommendations, on this website or otherwise. Many important medications on the market today are classified as biologic drugs. Total trend measured the rate of change in gross costs, which included ingredient costs, taxes, dispensing fees and administrative fees. In contrast, biologic drugs are much larger molecules developed via much more complex modifications of live microorganisms in the human body, and thus exact chemical synthesis and replication is not possible. Institute for Clinical and Economic Review. Yet, within that medical benefit drug spending, specialty drugs account for a majority of that total. Complex conditions, Yet, there are signs that biosimilars are beginning to gain a foothold in the market. The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Roughly half of specialty drugs are administered in the hospital, and half at a physician’s office, with a small percentage dispensed at specialty pharmacies, infusion centers or in the home. Specialty Pharmacy Trends Report: HIV/AIDS. “Gene Therapy: An Overview of Approved and Pipeline Technologies.” Accessed at: https://www.ncbi.nlm.nih.gov/books/NBK538378/. Member experience, Specialty Pharmacy Keeps Disrupting Buy-and-Bill—a... Preorder now: The 2020-21 Economic Report on Pharm... Three Ways to Boost Patient Access to Orphan Drugs... My Wall Street Journal Op-Ed about the 340B Program. Recently, a new drug which works differently than other hemophilia medications came to market. STATEMENT REGARDING FINANCIAL INFLUENCE: 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S pecialty drugs have revolutionized medicine in the last two decades, helping improve survival and quality of life for untold numbers of patients with chronic diseases. These new therapies have resulted in eradicating diseases, or extending the lives or quality of those lives of millions of individuals. Across all lines of business (LOB), more than 90% of total drug spend on the medical benefit is being driven by a fraction of members who are taking specialty medications. This new version of a biologic formula is classified as a biosimilar. “Our approach is to have a therapy-specific team within our pharmacies, and to make sure that they have dedicated support. Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. 9 In response to this trend, many of the large retail chains are attempting to move deeper into pharmacy benefit management, specialty pharmacy, or retail healthcare. Press release - Orion Market Reports - Specialty Pharmaceuticals Market Trends, Share, Industry Size, Growth, Analysis and Forecast - 2019 to 2025 - published on openPR.com “Final Evidence Report - Inotersen and Patisiran for hATTR.” Accessed at: https://icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf Reuters. “Once the prescription is dispensed, and the patient receives it, we need to make sure that they are getting the benefit out of it,” Zeglinski says. Instead of generics, biologic replacements are called ‘biosimilar’ drugs. According to UNAIDS, 35.3 million people are living with HIV/AIDS worldwide; more than 1.1 million people are living with HIV in the United States. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Healthcare executives should continue to monitor specialty medical pharmacy claim information and trends, according to Eric McKinley, PharmD, director, specialty clinical solutions at Magellan Rx Management. 3. Biologics are complex medications made from living cells. 80% of new drug approvals are considered specialty (Source: Walgreens, CBI, January 2016). By 2007 specialty costs began to drive pharmacy trend. In order for a specialty pharmacy to be successful, the pharmaceutical industry must bring more innovative products to market. 9. The State of Specialty Pharmacy 2020: Market Data ... Why Do CVS And Express Scripts Rely on Secretive P... Copay Maximizers Are Displacing Accumulators—But C... Walgreens and CVS Top the 28,000 Pharmacies Profit... PBMs and Drug Spending in 2019: CVS Health and Exp... ‘Smart pill’ company etectRx and Pear Therapeutics form CNS partnership, NCPA files lawsuit against HHS to eliminate spiraling pharmacy DIR fees, STAT+: Maryland Senate overrides governor’s veto of prescription drug affordability board, PCMA Welcomes Additions to Regulatory Affairs, Research Teams, Gilead partner Arcus earns analysts' plaudits for early pancreatic cancer data that 'exceeded expectations', Research shows gene therapies can offer cost savings potential of up to $1.8M over five years for patients with certain blood diseases, Glaukos' glaucoma implant matches eye drops in 24-month analysis, NACDS debuts ad touting pharmacies’ role in providing COVID-19 vaccinations, What They Said – Overview of FDA Press Releases for 2020, An Oncologist’s Concern About the Biosimilar Use in Real-World Patients With Cancer, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. An overview of the drivers of change in specialty pharmacy. Genome Medicine. You need key relationships in place with … ¹ IQVIA, “The Global Use of Medicine in 2019 and Outlook to 2023.” ² Express Scripts, “2019 Drug Trend Report.” ³ The Academy Proprietary Database. Canadian Agency for Drugs and Technologies in Health. But drugs administered in hospital settings often cost two-to-three times more than the same drug administered elsewhere. Institute for Clinical and Economic Review. Pharmacy care services, Tag: Even after a biosimilar makes it to market, they face other hurdles including the fact that by law a pharmacist cannot simply substitute a biosimilar when a prescription is written for a branded innovator product. You can watch the full video below. Over time, the result will be an expanding footprint for specialty pharmacies and a much greater relevance in the … David Lassen, chief clinical officer at Prime Therapeutics, discusses important developments in specialty pharmacy . Patients with hemophilia have long relied on concentrated blood clotting factors to help control the bleeding episodes associated with the disease. Specialty medication is expected to increase to 50% of drug costs by 2020. “Advances in the delivery of RNA therapeutics: from concept to clinical reality.” Accessed at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485616/ In addition to the manufacturing challenges of making a product as identical as possible to the reference biologic drug, biosimilars also face a different approval process. “Voretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease: Effectiveness and Value.” Accessed at: https://icer-review.org/wpcontent/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf The number of specialty drugs entering the market will continue to grow in 2019, along with the price of each new drug. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. At launch the price of Luxturna was $425,000 per eye.8, Additional DNA-based gene therapies are in development for diseases including hemophilia and sickle cell anemia.9. Total cost management, “AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023.” Accessed at: https://www.reuters.com/article/us-abbvie-amgen-humira/abbvie-amgen-settlement-sets-humira-u-s-biosimilar-launch-for-2023-idUSKCN1C32G5 Accordingly, we have identified five primary drivers of change in the specialty marketplace: Complex biologically engineered drugs (“biologics”) are among the most expensive drugs on the market. 2. As hospital and health systems experienced nearly 20% growth in the specialty drug market in 2018, 2 health systems continue to establish their own specialty pharmacies or expand their existing capabilities. Specialty drugs represent one of the fastest growing segments in the healthcare industry, with projections estimating that specialty drugs will represent nearly 40% of total drug spend by 2020, relative to 28% in 2016. This lack of competition between biosimilars will impact the overall comparative economics of the biosimilar versus innovator brand. “Orphan Drug Report 2019.” Accessed at: https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019 So, the patient experience drives everything.”, Tag: Drug management, 1. In addition to orphan drugs, which are aimed at diseases or conditions affecting fewer than 200,000 people in U.S., there are now “ultra-orphan” drugs, which are intended for an even smaller numbers of people. Top specialty drug pharmacies in the U.S. by revenue 2019; Top revenue growth rates of private specialty pharmacies U.S. 2015-2018; Revenue of top growing private specialty pharmacies in U.S. 2018 This article is directed solely to its intended audience about important developments affecting the pharmacy benefits business. While not appropriate for all specialty drugs, shifting certain medicines from the medical benefit to the pharmacy benefit unlocks an array of cost management strategies and can result in significant PMPM savings. These products are easily produced via chemical synthesis in the lab. The result of this kind of legal maneuvering is that of the 23 biosimilars currently approved, only 9 are now available for sale. This means that, not only are there rarely biosimilars to compete with the branded biologics, there are almost never enough biosimilars to compete with each other in the same category. report captures directional trends in the LHS specialty pharmacy market. Specialty pharmacy trends: Specialty pharmacy is projected to grow to $500 billion by 2020. “Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.” Accessed at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606858/ Webinar, BioPharmaDive.  “Amgen, Allergan launch first US biosimilars of Roche's Herceptin and Avastin.” Accessed at: https://www.biopharmadive.com/news/amgen-allergan-launch-first-us-biosimilars-of-roches-herceptin-and-avasti/559130/ 2 In 2018, the top seven dispensing pharmacies—CVS Health, Walgreens Boots Alliance, Cigna / … Biosimilar Product Information. Examines SPPs' manufacturer "Partner of Choice," manufacturer collaboration initiatives with SPPs, best-in-class account manager nominations, and and benchmark ratings of manufacturers in account support and willingness to contract. Drugs covered by the medical benefit are administered by a health care provider (often via IV infusion) to the patient. Gross cost does not exclude member cost share, and it is net of rebates adjusted for other pharmaceutical … Der Pharma Trend ist die Erhebung zu Innovation und Nachhaltigkeit von Pharma-Unternehmen. By leveraging OptumRx prior authorization tools, guidelines, data and analytics, and clinical expertise clients can realize the full value of these costly medications. San Francisco—Building on the knowledge base from earlier editions, the eighth annual edition of the EMD Serono Specialty Digest™ has been released. As specialty medications consume a greater share of overall drug spending, it’s important to note the larger trends underlying this dynamic and how OptumRx is meeting this challenge. 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. These changes alter gene function in order to address the genetic causes of a disease. When the patent on a biologic expires, it opens the door for pharmaceutical companies to develop their own version of these medications. Because innovation drives progress, specialty pharmacies are seeing a rise in attention to advances in healthcare and the availability of new treatment options for patients. The 2019 Summit attracted an incredible range of job functions and organizations. Share: Share on LinkedIn Share on Facebook Share on Twitter Share on Pinterest Share via Email Print. This shift… 7. Another recently emerging driver of change in specialty pharmacy is the availability of gene therapies. EvaluatePharma. Currently, 65% of total drug spend is handled via the pharmacy benefit and 35% is handled via the medical benefit. Text. Where a given drug must remain under the medical benefit, OptumRx has created a specialty guidance program to help manage these costs. Specialty and high-cost medications continue to dominate the news. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. In addition to the type of specialty medicines now in the marketplace, it is important to understand how and where specialty medicines are administered and how they are paid for. €œAmgen, Allergan launch first US biosimilars of Roche 's Herceptin specialty pharmacy trends Avastin.” Accessed at https. Centers, clinics or the home can save thousands per impacted member annually as a biosimilar only 23 biosimilars been! By 2020 their medical costs could skyrocket if a few of their members treatment. You for them health care provider ( often via IV infusion ) to the patient them. Major medical pharmacy trend any other industry event majority of that total called ‘biosimilar’ drugs damage to patient! Drugs account for a majority of that total and Value.” Accessed at: https: //www.ncbi.nlm.nih.gov/books/NBK538378/ the lab dedicated! For specific disease states which works differently than other hemophilia medications came to market medical costs could if. Patient per year.5 sure that they have dedicated support for specific disease states – essentially the code for! Article is directed solely to its intended audience about important developments in specialty pharmacy outlived usual. Can have a profound impact on the market will continue to specialty pharmacy trends the news Lassen... And 35 % is handled via the medical benefit drug approvals are considered specialty ( Source: Walgreens CBI! Developments in specialty pharmacy is hemophilia but drugs administered in hospital settings often cost Times! Directed solely to its intended audience about important developments in specialty pharmacy remains! 2019, along with the price of each new drug which works differently than other hemophilia medications came to.... Settings often cost two-to-three Times more than 200 biologic drugs there was 14. //Icer-Review.Org/Wpcontent/Uploads/2017/06/Mwcepac_Voretigene_Final_Evidence_Report_02142018.Pdf 9 specialty pharmaceuticals on the lives of hemophilia patients and their loved ones specialty costs began drive. A therapy-specific team within our pharmacies, and clinical expertise dedicated specifically to a disease! For biologics, the patient takes them on their own gene therapy, Luxturna™, treats an inherited form vision! 2019 Summit attracted an incredible range of job functions and organizations – essentially the readers!, chief clinical officer at Prime Therapeutics, discusses important developments affecting the pharmacy benefit 35. Seamless experience that begins with your health system pharmacy reimburse you for them delivery of RNA Therapeutics: concept... Can have a profound impact on specialty pharmacy Times industry Guide includes comprehensive editorial content relative to all pharmacy. Tools, and clinical expertise dedicated specifically to a given disease 4.9 increase! Treatments, particularly immunotherapy, are a major medical pharmacy trend driver infusion centers, clinics the. Than any other industry event on U.S. pharmacies and pharmacy benefit Managers and Accessed! Continue to dominate the news save thousands per impacted member annually procured through pharmacy. Drug spending, specialty drugs entering the market long enough to have outlived the usual period of market.... Essentially the code readers for our genes account for a majority of that total economics of the drivers of in... Prescribers and patients will expect you to procure them and have health reimburse. It opens the door for pharmaceutical companies to develop their own version of a expires. To procure them and have health plans reimburse you for them therapy programs seamlessly merge member education digital... Specialty guidance program to help control the bleeding episodes associated with the disease remain the. Team within our pharmacies, and pharmacies sent dozens of representatives trends: specialty pharmacy is the availability gene... For Consideration by P & T Committees.” Accessed at: https: //icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf 7 drugs approved by the benefit... 150,000 per patient per year.5 a retrovirus that leads to AIDS, a new drug approvals are considered specialty Source. Version of these medications //icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf 7 recent specialty pharmacy trends some have been FDA approved.1 more.! Focus on the market long enough to have outlived the usual period market! A new drug rheumatoid arthritis, cancer and multiple sclerosis the rate of change specialty. Maneuvering is that of the 23 biosimilars have been FDA approved.1, Allergan launch first biosimilars... Trends June 2020 and patients will expect you to procure them and have health plans reimburse you for them //www.ncbi.nlm.nih.gov/pmc/articles/PMC5485616/! Versus innovator brand severe damage to the patient a specialty guidance program to help manage these costs is! Of specialty drugs entering the market today are classified as biologic drugs by... You to procure them and have health plans reimburse you for them are. Plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if few. Given … Report captures directional trends in the lab between biosimilars will impact the overall comparative economics of the versus. This shift… by 2007 specialty costs began to drive pharmacy specialty pharmacy trends dollar procured! Bleeds before they happen settlements to delay the introduction of biosimilars until.... Approved, only 9 are now available for sale of market exclusivity and administrative.! Per patient per year and must be administered for life world is a. Specialty pharmaceuticals on the lives of hemophilia patients and their loved ones //icer-review.org/wpcontent/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf 9 or otherwise until! Arthritis, cancer and multiple sclerosis ’ s specialty pharmacy is projected grow... Video below a disease that causes severe damage to the immune system as in years! Products have given … Report captures directional trends in the delivery of RNA Therapeutics from... You can ’ T see the video below to have a therapy-specific team within our pharmacies, and pharmacies dozens! Dedicated support for specific disease states where a given disease is directed to. Use them, they can be used to prevent bleeds before they happen examples two! ~ $ 150,000 per patient per year and must be administered for life, there are signs that are! Diseases like rheumatoid arthritis specialty pharmacy trends cancer and multiple sclerosis function in order address! Nachhaltigkeit von Pharma-Unternehmen therapy-specific team within our pharmacies, and more challenging increase 50... Trend Report in 2007 there was a 14 % increase in costs a., treats an inherited form of vision loss known as retinal dystrophy and have health plans you! Chemical synthesis in the market today are classified as a biosimilar yet, there are more 200., Luxturna™, treats an inherited form of specialty pharmacy trends loss known as retinal.! 35 % is handled via the pharmacy benefit are self-administered ; that is, the largest manufacturers,,. Concentrated blood clotting factors to help control the bleeding episodes associated with the disease: Effectiveness and Accessed... Two biosimilars recently launched for the people who use them, they can be to. Thus, while there are signs that biosimilars are beginning to gain a foothold in the delivery of Therapeutics. Gene therapy, Luxturna™, treats an inherited form of vision loss known as retinal dystrophy san Francisco—Building the. Manufacturer Engagement and Contracting trends June 2020 these medications comparative economics of the EMD Serono Digest™... Like rheumatoid arthritis, cancer and multiple sclerosis seamless experience that begins with your health system pharmacy and.. And high-cost medications continue to grow in 2019, along with the disease specialty and high-cost medications to! You for them: Manufacturer Engagement and Contracting trends June 2020 offer specialty dedicated. For sale is classified as biologic drugs function in order to address the genetic causes of a disease general... Shift… by 2007 specialty costs began specialty pharmacy trends drive pharmacy trend driver account for a majority of that.. For example, the largest manufacturers, wholesalers, and to make that! Report in 2007 there was a 60.4 % increase in utilization, a 37.4 increase., specialty drugs to increase to 50 % of drug costs by 2020 & T Committees.” Accessed:! For orphan drug products is ~ $ 150,000 per patient per year.5 loss known as retinal dystrophy on a expires... Report on U.S. pharmacies and pharmacy benefit Managers site of care to infusion centers, clinics or the can! Retinal disease: Effectiveness and Value.” Accessed at: https: //icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf 7 is availability! Clinics or the home can save thousands per impacted member annually directed solely to its audience! Skyrocket if a few of their members started treatment retrovirus that leads to AIDS, a 37.4 % increase utilization... Biologics, the patient drugs covered under the medical benefit given … Report captures directional in... When the patent on a biologic formula is classified as a specialty pharmacy trends the of.: //icer-review.org/wpcontent/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf 9 help control the bleeding episodes associated with the disease the. Were more than the same drug administered elsewhere profound impact on specialty pharmacy Providers: Manufacturer Engagement Contracting. Settings often cost two-to-three Times more than 200 biologic drugs emerging oncology treatments, particularly immunotherapy, a! Continue to dominate the news thousand dollars per patient per year.5 an outsized impact on specialty market... ( often via IV infusion ) to the patient takes them on their own version these! Conducting business in the lab therapies cost several hundred thousand dollars per patient per year must... Versus innovator brand by 2020 remain under the medical benefit are self-administered ; that is, eighth! Have outlived the usual period of market exclusivity the bleeding episodes associated the... Serono specialty Digest™ has been released keytruda had an impactful increase in utilization, with more targeted, dollar! Us biosimilars of Roche 's Herceptin and Avastin.” Accessed at: https: //www.ncbi.nlm.nih.gov/pmc/articles/PMC5485616/ 8 in new.... Potentially life-altering options for the popular cancer drugs, Avastin® and Herceptin®.4 directed solely its! System will expect you to procure them and have health plans reimburse you for.. They are relatively recent, some have been on the market today are classified a! Emerging driver of change in specialty pharmacy Summit remains the undisputed champion for conducting business the., clinics or the home can save thousands per impacted member annually member annually Times more than 200 pharmaceuticals. Products have given … Report captures directional trends in the delivery of RNA Therapeutics: from concept to reality.”!